AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18949289 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin (NYS)
Number of subjects: 0
Study 18949289 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (FLU)
Number of subjects: 0
Study 18949289 — intervention group
Group type: COMPARATOR
Intervention: Deionized water (Control)
Number of subjects: 0
Study 18949289 — intervention group
Group type: COMPARATOR
Intervention: Orabase gel without active component (Control)
Number of subjects: 0
Study 15695321 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-8 (1.8 pmol.kg(‐1).min(‐1))
Number of subjects: 9
Study 15695321 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (0.9 pmol.kg(‐1).min(‐1))
Number of subjects: 9
Study 15695321 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-8 (1.8 pmol.kg(‐1).min(‐1)) and GLP-1 (0.9 pmol.kg(‐1).min(‐1))
Number of subjects: 9
Study 15695321 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 9
Study 11838857 — intervention group
Group type: EXPERIMENTAL
Intervention: ASMP course (6 week course)
Number of subjects: 113
Study 11838857 — intervention group
Group type: COMPARATOR
Intervention: ASMP manual (control)
Number of subjects: 113
Study 10084271 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily (add-on therapy to timolol)
Number of subjects: 148
Study 10084271 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 2% three times daily (add-on therapy to timolol)
Number of subjects: 148
Study 10084271 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily (switch from timolol)
Number of subjects: 148
Study 8747987 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (HD-CY) or dose-escalated ifosfamide/mitoxantrone followed by filgrastim (R-metHuG-CSF, 300 micrograms/day)
Number of subjects: 70
Study 8747987 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential high-dose treatment
Number of subjects: 70
Study 8747987 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 70
Study 1905614 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate disodium (Didronel; 750 mg orally daily)
Number of subjects: 9
Study 6367862 — intervention group
Group type: COMPARATOR
Intervention: CMF (cytoxan, methotrexate, and 5-fluorouracil)
Number of subjects: 312
Study 6367862 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF plus tamoxifen (CMFT)
Number of subjects: 312
Study 6367862 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFT plus BCG vaccinations
Number of subjects: 312
Study 6367862 — intervention group
Group type: EXPERIMENTAL
Intervention: ER measurements in primary tumor
Number of subjects: 312
Study 31046082 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg administered intravenously every 3 weeks until cancer progression, toxicity, or completion of 2 years (Cohort A)
Number of subjects: 376
Study 31046082 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg administered intravenously every 3 weeks until cancer progression, toxicity, or completion of 2 years (Cohort B)
Number of subjects: 376
Study 31046082 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg administered intravenously every 3 weeks until cancer progression, toxicity, or completion of 2 years (Cohort A and B)
Number of subjects: 376
Study 30198412 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside condition
Number of subjects: 573
Study 30198412 — intervention group
Group type: COMPARATOR
Intervention: Policy condition
Number of subjects: 573
Study 27430301 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine follow-up care in the community
Number of subjects: 0
Study 27430301 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital outpatient care
Number of subjects: 0
Study 24256611 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0
Study 24256611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22520738 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychotherapy (STT)
Number of subjects: 326
Study 22520738 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term psychotherapy (LPP)
Number of subjects: 326
Study 20414536 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRS-CPB
Number of subjects: 101
Study 18640457 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimebon (60 mg/day, 20 mg three times a day)
Number of subjects: 183
Study 18640457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 16143731 — intervention group
Group type: EXPERIMENTAL
Intervention: IPSRT (Interpersonal and Social Rhythm Therapy)
Number of subjects: 175
Study 16143731 — intervention group
Group type: COMPARATOR
Intervention: ICM (Intensive Clinical Management)
Number of subjects: 175
Study 12133397 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg + MPA 2 mg + Ca-D 1 tablet daily (Group A)
Number of subjects: 236
Study 12133397 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.3 mg + MPA 2 mg + Ca-D 1 tablet daily (Group B)
Number of subjects: 236
Study 12133397 — intervention group
Group type: COMPARATOR
Intervention: Cal-D 1 tablet daily alone (Group C)
Number of subjects: 236
Study 12133397 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal bleeding rate in Group A
Number of subjects: 236
Study 12133397 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrium biopsies in Groups A and B
Number of subjects: 236
Study 12133397 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events in Group A
Number of subjects: 236
Study 10394089 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine 5 mg (n = 6)
Number of subjects: 17
Study 10394089 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 2.4 mg (n = 6)
Number of subjects: 17
Study 10394089 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile water, n = 5)
Number of subjects: 17
Study 8749725 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Number of subjects: 0
Study 8749725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2202773 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin Base Filmtab (nonenteric-coated) at 1 g/d
Number of subjects: 368
Study 2202773 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin Base Filmtab (nonenteric-coated) at 2 g/d
Number of subjects: 368
Study 2202773 — intervention group
Group type: COMPARATOR
Intervention: Eryc (enteric-coated) at 1 g/d
Number of subjects: 368
Study 2202773 — intervention group
Group type: COMPARATOR
Intervention: Eryc (enteric-coated) at 2 g/d
Number of subjects: 368
Study 45211 — intervention group
Group type: EXPERIMENTAL
Intervention: IV almitrine 0.5 mg/kg
Number of subjects: 16
Study 45211 — intervention group
Group type: COMPARATOR
Intervention: IV doxapram 1 mg/kg
Number of subjects: 16
Study 30146666 — intervention group
Group type: EXPERIMENTAL
Intervention: Reimagine (online symptom self-management curriculum)
Number of subjects: 89
Study 30146666 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 89
Study 28693447 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-education intervention (n = 170) at 24 and 34 weeks of pregnancy
Number of subjects: 339
Study 28693447 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 169)
Number of subjects: 339
Study 28693447 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-education intervention
Number of subjects: 339
Study 28693447 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 339
Study 26189067 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational group (oxaliplatin + fluorouracil)
Number of subjects: 1236
Study 26189067 — intervention group
Group type: COMPARATOR
Intervention: Control group (fluorouracil only)
Number of subjects: 1236
Study 26189067 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational group (oxaliplatin + fluorouracil during chemoradiotherapy)
Number of subjects: 1236
Study 26189067 — intervention group
Group type: COMPARATOR
Intervention: Control group (fluorouracil during chemoradiotherapy)
Number of subjects: 1236
Study 26189067 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational group (oxaliplatin + leucovorin + fluorouracil during adjuvant chemotherapy)
Number of subjects: 1236
Study 26189067 — intervention group
Group type: COMPARATOR
Intervention: Control group (fluorouracil + leucovorin during adjuvant chemotherapy)
Number of subjects: 1236
Study 26189067 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational group (preoperative and postoperative treatment)
Number of subjects: 1236
Study 26189067 — intervention group
Group type: COMPARATOR
Intervention: Control group (preoperative and postoperative treatment)
Number of subjects: 1236
Study 24026523 — intervention group
Group type: EXPERIMENTAL
Intervention: EX/RP (exposure and ritual prevention)
Number of subjects: 100
Study 24026523 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 100
Study 24026523 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study 23241242 — intervention group
Group type: EXPERIMENTAL
Intervention: ADDITION-PRO cohort participants
Number of subjects: 2182
Study 20840711 — intervention group
Group type: EXPERIMENTAL
Intervention: Current douching practices among women
Number of subjects: 41
Study 20840711 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence of health care providers and family members
Number of subjects: 41
Study 20840711 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of vaginal douching
Number of subjects: 41
Study 20840711 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic value of vaginal douching
Number of subjects: 41
Study 20840711 — intervention group
Group type: EXPERIMENTAL
Intervention: Education on risks of vaginal douching
Number of subjects: 41
Study 17249845 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (PS-341)
Number of subjects: 0
Study 17249845 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactacystin
Number of subjects: 0
Study 15308586 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato oleoresin extract (3 capsules daily for 2 weeks, each containing 4.88 mg lycopene, 0.48 mg phytoene, 0.44 mg phytofluene, and 1.181 mg alpha-tocopherol)
Number of subjects: 27
Study 15308586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 11160057 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA (10 mg)
Number of subjects: 24
Study 11160057 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐arginine (375 mg)
Number of subjects: 24
Study 11160057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11160057 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA vs L‐arginine
Number of subjects: 24
Study 11160057 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA and L‐arginine
Number of subjects: 24
Study 9748428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 1000 microgram administered twice daily at 08:00 h and 20:00 h
Number of subjects: 10
Study 9748428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9748428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 10
Study 8046314 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirprofen (400 mg t.i.d.)
Number of subjects: 40
Study 8046314 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (500 mg b.i.d.)
Number of subjects: 40
Study 3149456 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy plus nonsteroid antiandrogen (Anandron)
Number of subjects: 0
Study 3149456 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy plus placebo
Number of subjects: 0
Study 3149456 — intervention group
Group type: EXPERIMENTAL
Intervention: Total androgen blockade
Number of subjects: 0
Study 29334983 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check‐Up 4 Health (FCU4Health) program
Number of subjects: 350
Study 29334983 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 350
Study 26676676 — intervention group
Group type: EXPERIMENTAL
Intervention: Early start of flap training (FT) on day 3
Number of subjects: 49
Study 26676676 — intervention group
Group type: COMPARATOR
Intervention: Standard start of flap training (FT) on day 7
Number of subjects: 49
Study 24905321 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride 2.5 mg
Number of subjects: 42
Study 24905321 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride 5 mg
Number of subjects: 42
Study 24905321 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride 10 mg
Number of subjects: 42
Study 24905321 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride (all doses)
Number of subjects: 42
Study 23536652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin monotherapy for 6 weeks
Number of subjects: 12
Study 23536652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23536652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin monotherapy
Number of subjects: 12
Study 20832550 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboelastography (TEG) monitoring
Number of subjects: 28
Study 20832550 — intervention group
Group type: COMPARATOR
Intervention: Standard laboratory measures of blood coagulation monitoring
Number of subjects: 28
Study 20832550 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG monitoring
Number of subjects: 28
Study 20832550 — intervention group
Group type: COMPARATOR
Intervention: TEG monitoring and Standard laboratory measures
Number of subjects: 28
Study 18607338 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 0
Study 15757062 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal product use
Number of subjects: 227
Study 15757062 — intervention group
Group type: COMPARATOR
Intervention: Preoperative assessment
Number of subjects: 227
Study 12668582 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral linezolid (375, 500, or 625 mg)
Number of subjects: 0
Study 12668582 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous linezolid (500 or 625 mg)
Number of subjects: 0
Study 12668582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10565448 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified human milk (group II)
Number of subjects: 3
Study 10565448 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm formula (group III)
Number of subjects: 3
Study 10565448 — intervention group
Group type: COMPARATOR
Intervention: Human milk alone (group I)
Number of subjects: 3
Study 8927676 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder with comorbid ADHD
Number of subjects: 30
Study 8927676 — intervention group
Group type: COMPARATOR
Intervention: Bipolar disorder without ADHD
Number of subjects: 30
Study 1671434 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine or phenobarbitone treatment
Number of subjects: 302
Study 6306348 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiation therapy (Cytoxan, CCNU, methotrexate + radiation to brain, chest, and abdomen)
Number of subjects: 145
Study 6306348 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (Cytoxan, CCNU, methotrexate)
Number of subjects: 145
Study 6306348 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiation therapy
Number of subjects: 145
Study 6306348 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial response to therapy
Number of subjects: 145
Study 6306348 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 145
Study 31026780 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TNS group
Number of subjects: 24
Study 31026780 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 24
Study 29178317 — intervention group
Group type: EXPERIMENTAL
Intervention: Client‐driven, customized self‐management program with up to 3 in‐home visits from a registered nurse or registered dietitian, a monthly group wellness program, monthly provider team case conferences, and care coordination and system navigation.
Number of subjects: 159
Study 29178317 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 159
Study 26739392 — intervention group
Group type: EXPERIMENTAL
Intervention: High hs‐TnT level (≥14 ng/l) in diabetic group
Number of subjects: 1786
Study 26739392 — intervention group
Group type: EXPERIMENTAL
Intervention: hs‐TnT in multivariate model
Number of subjects: 1786
Study 26739392 — intervention group
Group type: EXPERIMENTAL
Intervention: hs‐CRP, B‐type natriuretic peptide, and sST2 in diabetic group
Number of subjects: 1786
Study 26739392 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 in nondiabetic group
Number of subjects: 1786
Study 26739392 — intervention group
Group type: EXPERIMENTAL
Intervention: hs‐CRP in nondiabetic group
Number of subjects: 1786
Study 26739392 — intervention group
Group type: EXPERIMENTAL
Intervention: hs‐TnT inclusion in model
Number of subjects: 1786
Study 24413493 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate Nugent score (4-6)
Number of subjects: 2920
Study 24413493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis (Nugent score 7-10)
Number of subjects: 2920
Study 24413493 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis excluding participants with TV at baseline
Number of subjects: 2920
Study 22085757 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus concreteness training (CNT)
Number of subjects: 121
Study 22085757 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus relaxation training (RT)
Number of subjects: 121
Study 22085757 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 121
Study 21290836 — intervention group
Group type: COMPARATOR
Intervention: Medication (antihistamine and anti-HP infection)
Number of subjects: 92
Study 21290836 — intervention group
Group type: COMPARATOR
Intervention: Acupoint catgut embedding therapy
Number of subjects: 92
Study 21290836 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication combined with acupoint catgut embedding therapy
Number of subjects: 92
Study 17890862 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine 5 mg b.i.d.
Number of subjects: 386
Study 17890862 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine 7.5 mg b.i.d.
Number of subjects: 386
Study 15050376 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused analgesia
Number of subjects: 15
Study 15050376 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized relaxation
Number of subjects: 15
Study 11549982 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate 42 mcg via metered dose inhaler twice daily
Number of subjects: 429
Study 11549982 — intervention group
Group type: COMPARATOR
Intervention: Oral zafirlukast 20 mg twice daily
Number of subjects: 429
Study 9613227 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot light (S)
Number of subjects: 16
Study 9613227 — intervention group
Group type: EXPERIMENTAL
Intervention: General light (G)
Number of subjects: 16
Study 9613227 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed light (M)
Number of subjects: 16
Study 7640145 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sumatriptan 100 mg
Number of subjects: 26
Study 7640145 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sumatriptan 200 mg
Number of subjects: 26
Study 7640145 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sumatriptan 50 mg
Number of subjects: 26
Study 7640145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 2502417 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg simvastatin
Number of subjects: 34
Study 2502417 — intervention group
Group type: COMPARATOR
Intervention: 16 g cholestyramine
Number of subjects: 34
Study 1107359 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular nefopam HCl 20 mg
Number of subjects: 100
Study 1107359 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular pethidine 50 mg
Number of subjects: 100
Study 1107359 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 100
Study 1107359 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nefopam HCl 60 mg t.i.d. for three days
Number of subjects: 100
Study 1107359 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo t.i.d. for three days
Number of subjects: 100
Study 29170121 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective feelings of personal relative deprivation (PRD)
Number of subjects: 0
Study 29170121 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimentally-induced PRD
Number of subjects: 0
Study 26796706 — intervention group
Group type: EXPERIMENTAL
Intervention: HP35 (35% hydrogen peroxide)
Number of subjects: 48
Study 26796706 — intervention group
Group type: COMPARATOR
Intervention: HP6 (6% hydrogen peroxide with nitrogen-doped titanium oxide)
Number of subjects: 48
Study 24503910 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized deliberate practice (DP) on a virtual reality simulator
Number of subjects: 16
Study 24503910 — intervention group
Group type: COMPARATOR
Intervention: Conventional residency training (Control)
Number of subjects: 16
Study 24101183 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha neurofeedback training (20 sessions within 20 days)
Number of subjects: 13
Study 24101183 — intervention group
Group type: COMPARATOR
Intervention: Non-neurofeedback control group (no training sessions)
Number of subjects: 13
Study 20575304 — intervention group
Group type: EXPERIMENTAL
Intervention: Sizhi‐Xifang treatment in the treatment group (24 cases) after incision healing
Number of subjects: 49
Study 20575304 — intervention group
Group type: COMPARATOR
Intervention: Minimal invasive percutaneous plate treatment in the control group
Number of subjects: 49
Study 19048106 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioreduction (drainage of 2000 ml fluid, range 700‐3500 ml)
Number of subjects: 40
Study 19048106 — intervention group
Group type: COMPARATOR
Intervention: Control procedures
Number of subjects: 40
Study 15124952 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis (HD)
Number of subjects: 42
Study 15124952 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 42